Strategy analysis

Immuno-oncology continues to draw pharma companies to the deal table.

August 5, 2019

Pharma Externalization Strategies 2016: Externalization is Critical to Pharma Revenue

Pharmaceutical companies constantly re-assess their pipelines and portfolios to determine the best strategies for their business.

October 17, 2016

Multiple Sclerosis (MS) KOL Interview – US, Midwest

In this interview, a US-based key opinion leader (KOL) discusses typical prescribing habits for disease-modifying therapies (DMTs) in MS. This includes first-generation DMTs and the newer, more potent entrants like Ocrevus, as well as late-stage pipeline DMTs.

March 2, 2020

Alzheimer’s KOL Interview

$399.00

KOL is optimistic on amyloid-targeted therapy and believes IV therapy will be tolerated if approved.

October 21, 2015

Post-Clinical Trials on Alzheimer’s Disease (CTAD) 2016 Survey

Biomedtracker conducted a 5-question survey of 51 United States and 47 European (from France, Germany, Italy, Spain and United Kingdom) neurologists who currently treat patients in all stages of Alzheimer’s disease and who followed data presented at Clinical Trials on Alzheimer’s Disease (CTAD) 2016 to gauge their views on the pipeline anti-amyloid beta monoclonal antibodies solanezumab (LLY) and aducanumab (BIIB) and projected use of these potentially disease-modifying drugs if FDA-approved.

March 9, 2017

Depression KOL Interview – US #2

A US expert in the depression field dives into the treatment algorithm, critical unmet needs, and pipeline drugs such as SAGE-217 and AXS-05.

March 2, 2021

Datamonitor Healthcare HIV KOL Interview – UK

A UK key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

January 25, 2019

Atopic Dermatitis and Psoriasis KOL Interview – UK

This interview with a UK-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.

November 18, 2021

SGLT-2 Pulse Survey

We surveyed primary care physicians (n=10) and endocrinologists (n=10) to see how SGLT-2 inhibitors and the combo pills will be used and what the potential impact of usage with GLP-1 agonists may have.

August 25, 2014

HIV Pre-Exposure Prophylaxis (HIV PrEP) KOL Interview – US #2

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HIV PrEP. Drug pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include islatravir and cabotegravir.

August 10, 2021

Datamonitor Healthcare HIV KOL Interview – US #2

A US key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

January 25, 2019

Asthma and COPD KOL Interview

KOL thinks that the biggest challenge to treating COPD is cost, even with a very low population of uninsured people.

February 29, 2016

New Pharma Models for a New Healthcare Era

This analysis includes insights from eight interviewed experts from pharma, medical device, or digital health companies.

December 20, 2018

UK Generics and Biosimilars

Prescribing by international non-proprietary name, pharmacist incentives, and the high price differential between the brands and their generic alternatives are the key drivers of the generics market in the UK.

November 2, 2016

Datapack – Pharmaprojects Pharma R&D Annual Review 2017

$1,999.00

This datapack presents the supporting data behind the seminal white paper, Pharma R&D Annual Review 2017. The white paper is available for free for Biomedtracker subscribers.

April 18, 2017